Cure My Disease

Don't miss your cure!

 Log in / Sign up

New asthma pill shows promise in early trial

NCT ID NCT05935332

Disease control Sponsor: RAPT Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested an experimental oral drug called RPT193 in 38 adults with moderate-to-severe asthma that was not fully controlled by standard inhalers. The goal was to see if RPT193 could reduce asthma attacks and improve lung function. The trial was terminated early, so final results are not available, but the data may still inform future research.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
RPT193
What this could lead to
If successful, RPT193 could offer a new oral option to help control moderate-to-severe asthma and reduce flare-ups.
What could go wrong
This was a small, early-phase trial that was terminated, so results are limited. It is unclear if RPT193 will prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

38 people

The number who actually took part.

Started

Jul 2023

Finished

Jun 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Physician diagnosis of asthma for ≥6 months * Pre-bronchodilator FEV1 of \>40% and \<80% * History of treatment with corticosteroid or hospitalization for worsening asthma * Medium- or high-dose inhaled corticosteroid use Exclusion Criteria: * History of smoking/vaping * History of severe COVID * Serious and/or uncontrolled pulmonary, cardiac, immune system conditions * Requires systemic oral or IV corticosteroids in the month prior to screening

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

asthma T2-high asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma

Contacts and locations

Locations

  • Allergy and Asthma Associates of Santa Clara Valley Research Center

    San Jose, California, 95117, United States

  • Allergy, Asthma & Sinus Ceneter SC

    Greenfield, Wisconsin, 53228, United States

  • Allianz Research Institute

    Westminster, California, 92683, United States

  • Allianz Research Institute CO

    Aurora, Colorado, 80014, United States

  • Bensch Clinical Research LLC

    Stockton, California, 95207, United States

  • Centrum Diagnostyczno Terapeutyczne MEDICUS Sp. z o.o. - Szpital

    Lubin, 59-300, Poland

  • Centrum Medycyny Oddechowej Mróz Spółka Jawna

    Bialystok, 15-044, Poland

  • Clinical Research Trials of Florida

    Tampa, Florida, 33607, United States

  • Coral Research Clinical Corp

    Miami, Florida, 33186, United States

  • Diagnostic-Consultative Center Convex Ltd.

    Sofia, 1680, Bulgaria

  • IP Clinic Sp. z.o.o

    Lodz, 90-752, Poland

  • Lekarze Specjaliści - J. Małolepszy i Partnerzy

    Wroclaw, 54-239, Poland

  • MediTrial s.r.o

    Jindřichův Hradec, 377 01, Czechia

  • Medical Center "ResearchExpert" Ltd

    Varna, 9000, Bulgaria

  • Medical Center "Zadrave-1"

    Kozloduy, 3320, Bulgaria

  • Medical Center Excelsior

    Sofia, 1407, Bulgaria

  • Metroplex Pulmonary & Sleep Center

    McKinney, Texas, 95069, United States

  • Michal Bogacki - Dobrostan

    Wroclaw, 53-301, Poland

  • NZOZ Poradnie Specjalistyczne Atopia

    Krakow, 31-159, Poland

  • OK Clinical Research LLC

    Edmond, Oklahoma, 73034, United States

  • San Marcos Research Clinic

    Miami Lakes, Florida, 33014, United States

  • Sonce Medical Research

    Miami, Florida, 33133, United States

  • Specialized Hospital for Active Treatment of Pneumo-Phthisiatric Diseases - Vratsa

    Vratsa, 3000, Bulgaria

  • Specjalistyczna Przychodnia Lekarska Alergo-Med sp. z o.o

    Poznan, 61-578, Poland

  • Trialmed CRS (Piotrków Trybunalski)

    Piotrkow Trybunalski, 97-300, Poland

  • Trialmed Sp z. o.o.o CRS Warszawa

    Warsaw, Solipska, 02-482, Poland

  • University Multiprofile Hospital for Active Treatment

    Stara Zagora, 6003, Bulgaria

  • Velocity Clinical Research Grants Pass

    Grants Pass, Oregon, 97527, United States

  • Western Sky Medical Research

    El Paso, Texas, 79903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.